Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVX502
- Development stage
- Phase 2
- Lead developer
- AlphaVax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
AVX502 is an investigational alphavirus replicon-based vaccine developed by AlphaVax for the prevention of seasonal influenza. The vaccine expresses the hemagglutinin (HA) protein from the Influenza A/Wyoming/03/2003 strain using a proprietary alphavirus vector platform. Its mechanism of action is immunostimulation—eliciting both antibody and T cell responses against influenza virus antigens. AVX502 has been evaluated in Phase II clinical trials for the prevention of influenza virus infections, including studies in adults and elderly populations[1][2][5].
- Other names
- Influenza virus vaccine - AlphaVaxSeasonal influenza vaccine for elderly - AlphaVax
02
Targets
HA (Hemagglutinin)
Beyond the preview
Go deeper on AVX502.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVX502.